NASDAQ:URGN Urogen Pharma Q3 2026 Earnings Date & Estimates $36.83 -0.15 (-0.41%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$36.83 0.00 (-0.01%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Urogen Pharma is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for 10:00 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 5, 2026TimeBefore Market OpensConference Call10:00 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Urogen Pharma in Q3 2026Urogen Pharma is expected to post earnings of $0.1025 per share on revenue of $90.58 million. In the same quarter a year earlier Urogen Pharma reported -$0.69 per share on revenue of $27.48 million. Urogen Pharma last reported on August 5, 2026, posting -$0.28 per share and missing the -$0.2650 consensus estimate. Urogen Pharma has beaten the consensus EPS estimate in 4 of its last 8 quarters.Consensus EstimatesConsensus EPS$0.1025Expected Revenue$90.58 millionPrior-Year EPS-$0.69Prior-Year Revenue$27.48 millionExpected Revenue Growth+229.6%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.28 (Missed by -$0.0150)Last Quarter Revenue$72.46 millionEPS Beat Rate4 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Urogen Pharma Q3 2026 Earnings FAQ When does Urogen Pharma report Q3 2026 earnings? Urogen Pharma (NASDAQ:URGN) is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. What time is Urogen Pharma's Q3 2026 earnings call? Urogen Pharma's Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 10:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Urogen Pharma? Analysts expect Urogen Pharma to post earnings of $0.1025 per share for Q3 2026. How much revenue is Urogen Pharma expected to report? The consensus revenue estimate for Urogen Pharma is $90.58 million for Q3 2026. Urogen Pharma Earnings HeadlinesUroGen Pharma (URGN) Stock Looks Fairly Valued On Its Sales BaseSeptember 25, 2026 | finance.yahoo.comIs UroGen’s (URGN) Commercial Engine Strong Enough To Fund Its Pipeline Ambitions?September 23, 2026 | finance.yahoo.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions. | Weiss Ratings (Ad)Urogen Pharma: Upside After Bladder Cancer LaunchSeptember 9, 2026 | seekingalpha.comUroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 4, 2026 | globenewswire.comUroGen Pharma to Present at Upcoming Investor ConferencesSeptember 2, 2026 | globenewswire.comSee More Urogen Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Urogen Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Urogen Pharma and other key companies, straight to your email. Email Address About Urogen PharmaUrogen Pharma (NASDAQ:URGN) Ltd. is a biopharmaceutical company focused on developing and commercializing therapies for cancers of the urinary tract. The company’s platform is based on RTGel, a proprietary reverse-thermal hydrogel designed to retain medicines in the urinary tract and provide localized treatment while limiting systemic exposure. UroGen’s lead commercial product is JELMYTO (mitomycin), a gel-based therapy approved by the U.S. Food and Drug Administration for the primary chemoablation of low-grade upper tract urothelial cancer in adults. The company is also developing UGN-102, an investigational formulation of mitomycin intended for the treatment of low-grade, intermediate-risk non-muscle-invasive bladder cancer. Founded in 2004, UroGen is headquartered in Princeton, New Jersey, and has operations connected to Israel, where the company was established. Its commercial activities are primarily focused on the United States, while its clinical development programs are intended to support broader treatment options for patients with urological cancers. Elizabeth Barrett serves as the company’s president and chief executive officer.View Urogen Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
